

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number

WO 2022/098955 A9

(43) International Publication Date
12 May 2022 (12.05.2022)

(51) International Patent Classification:

A61K 39/395 (2006.01) A61P 37/00 (2006.01)
A61P 21/04 (2006.01) C07K 16/28 (2006.01)
A61P 29/00 (2006.01)

63/219,155

07 July 2021 (07.07.2021)

US

(71) Applicant: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(21) International Application Number:

PCT/US2021/058188

(72) Inventors: RAMCHANDRAN, Sindhu; 1400 McKean
Road, Spring House, Pennsylvania 19477 (US). SUN,
Hong; 1400 McKean Road, Spring House, Pennsylvania
19477 (US). DENNEY, William; 124 Forest St., Wa-
tertown, Massachusetts 02472 (US). ARROYO, Santia-
go; 177 Huntington Ave. Ste. 1700, PMB 93344, Boston,
Massachusetts 02115 (US). LING, Leona; 1400 McKean
Road, Spring House, Pennsylvania 19477 (US). LEU, Jo-
celyn; 1400 McKean Road, Spring House, Pennsylvania
19477 (US). JIN, Jianhua; 6 Spring Valley Road, Belmont,
Massachusetts 02478 (US). JOUVIN, Marie-Helene; 107
Whitcomb Ave., Jamaica Plain, Massachusetts 02130 (US).
KARCHER, Keith; 1125 Trenton-Harbourton Road, Ti-
tusville, New Jersey 08560 (US). BLACK, Shawn; 1400
McKean Road, Spring House, Pennsylvania 19477 (US).

(22) International Filing Date:

05 November 2021 (05.11.2021)

(25) Filing Language:

English


(26) Publication Language:

English

(30) Priority Data:

63/110,884	06 November 2020 (06.11.2020)	US
63/137,972	15 January 2021 (15.01.2021)	US
63/173,126	09 April 2021 (09.04.2021)	US
63/173,919	12 April 2021 (12.04.2021)	US
63/174,423	13 April 2021 (13.04.2021)	US
63/175,440	15 April 2021 (15.04.2021)	US
63/203,075	07 July 2021 (07.07.2021)	US
63/203,077	07 July 2021 (07.07.2021)	US

(54) Title: FCRN ANTIBODIES AND METHODS OF USE THEREOF



Abbreviations: FcRn = neonatal Fc receptor; SD = standard deviation.

FIG. 1

(57) Abstract: Methods for dosing of antibodies to human neonatal Fc receptor (FcRn) are described. The anti-FcRn antibodies are useful, e.g., to promote clearance of autoantibodies in a subject, to suppress antigen presentation in a subject, to block an immune response, e.g., block an immune complex-based activation of the immune response in a subject, or to treat immunological diseases (e.g., autoimmune diseases) in a subject.

[Continued on next page]



WO 2022/098955 A9

ZHU, Yaowei; 965 Chesterbrook Boulevard, Wayne, Pennsylvania 19087 (US).

(74) **Agent: MCEWAN, Przemyslaw P.**; Troutman Pepper Hamilton Sanders LLP, 400 Berwyn Park, 899 Cassatt Road, Berwyn, Pennsylvania 19312 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) **Date of publication of this corrected version:**
09 June 2022 (09.06.2022)

(15) **Information about Correction:**
see Notice of 09 June 2022 (09.06.2022)